Lupus Erythematosus, Systemic, Adverse Effects
Conditions
Keywords
Myelosuppression, Infection, Nausea
Brief summary
The purpose of this study is to investigate the relationship between the side effects of cyclophosphamide in the treatment of systemic lupus erythematosus (SLE) in Han Chinese and the genetic polymorphisms of drug metabolizing enzymes and pharmacokinetics of cyclophosphamide.
Detailed description
Cyclophosphamide is a widely applied agent in treatment of systemic lupus erythematosus. As an alkylating agent, cyclophosphamide is able to induce several side effects, including thinned hair, loss of appetite, nausea, vomiting, infection, myelosuppression, etc. However, the remarkable variability of the reactions to the drug -- the incidence of side effect or the outcome of the treatment -- has been observed among patients. Cyclophosphamide is a pro-drug, which require some enzymes in the liver to transform it into an active chemical to arouse alkylating function. And then it undergoes a series of detoxification steps catalyzed by the specific metabolic enzymes. This study is designed to explore the genetic variation among individuals in the key processes of the activation and elimination of cyclophosphamide in order to find out whether these genetic factors are associated to the side effects or efficacy. The further understanding into the factors concerning on the drug might imply possible solution to minimize the incidence of side effects in patients of systemic lupus erythematosus.
Interventions
GENETICPolymorphism Analysis
Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
DRUGCyclophosphamide
intravenous injection, 0.2g, once every two days
laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
Sponsors
First Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. The patients must have been diagnosed as SLE according to the American College of Rheumatology (ACR) criteria published in 1997. 2. The patients must sign the informed consent. And for the patients who are under 18 years old, both the signatures of their legal guardians and that of the patients are required on the written informed consent. 3. The patients are receiving the standard regimen of 0.2g cyclophosphamide given as intravenous injection once every two days.
Exclusion criteria
1. Pregnant women, women in breast-feeding period and the women who refuse to take contraception measures during treatment. 2. Patients with poor compliance. 3. Patients who are also diagnosed of cancer or who are receiving cyclophosphamide in treatment of cancer, or other anti-cancer therapy.
Countries
China
Outcome results
None listed